PromarkerD features at American Diabetes Association 79th Scientific Sessions saying diabetics deserve to know their future kidney disease status
- Proteomics International meeting with US tier 1 national diagnostic groups to expand global roll-out of PromarkerD including EU and Mexico
SAN FRANCISCO, CA, Jun, 07 2019 - (ACN Newswire) - Proteomics International (ASX: PIQ) has been invited to feature on the American Diabetes Association (ADA) TV News Network as a key opinion leader (KOL) on diabetic kidney disease diagnostics, which includes an update on PromarkerD, during the ADA 79th Scientific Sessions conference in San Francisco, June 7-11, 2019.
PromarkerD will also be presented at booth 1738 in the ADA 79th Scientific Sessions Exhibit Hall. PromarkerD is a blood test that can diagnose and predict whether a patient will develop diabetic kidney disease, and predict the onset of diabetic kidney disease before clinical symptoms appear.
PromarkerD clinical data, first launched at the American Diabetes Association Annual Scientific Sessions 2017 and published in the prestigious journal Diabetes Care, shows PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years.
Proteomics International Managing Director Dr Richard Lipscombe outlined the impact PromarkerD will have saving lives and healthcare costs, and the global roll-out plans for PromarkerD in the exclusive interview to be broadcast at the industry's leading conference.
See the interview here: http://bit.ly/PromarkerD-ADA / https://youtu.be/X_KScqaqpvc
"PromarkerD is world-beating technology and needs to get into the hands of specialists and physicians to stem the tsunami of kidney disease which is causing over 40,000 deaths per year in the US, with related healthcare spending exceeding US$100 billion annually," commented Dr Lipscombe.
"There is nothing else like PromarkerD available - it's the world's leading predictive test for diabetic kidney disease according to analysts in our sector."
He said the test will also make a major difference for insurance companies because it will cut dramatically the number of people who are unaware they have progressive kidney disease so they can do something about it immediately, and so reduce treatments costs.
"The US population with diabetes deserve to know their kidney disease status."
There are approximately 260,000 CLIA certified laboratories in the US, the majority of which have diagnostic capabilities to license the PromarkerD test.
PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by global research house Frost & Sullivan in its independent industry report titled 'Biomarkers Enabling Diabetes and Obesity Management.'
PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending.
The immunoassay reagents for PromarkerD can be configured into a Laboratory Developed Test (LDT) for use by certified laboratories.
This parallels the LDT using the existing mass spectrometry platform, and offers a better fit for mainstream diagnostics providers where the immunoassay platform is more standard than advanced mass spectrometry technology.
The dual technology platforms offer greater choice to the large market of certified clinical laboratories that conduct these types of test.
In parallel with the fast roll-out of PromarkerD using the Laboratory Developed Test route, Proteomics International is also pursuing registration of the kit version of the test for larger scale adoption as market demand increases.
About PromarkerD (www.PromarkerD.com)
PromarkerD is a predictive diagnostic test for diabetic kidney disease. In clinical studies presented at the American Diabetes Association Annual Scientific Sessions [ASX: 13 June 2017] and published in the prestigious journal Diabetes Care [ASX: 6 Sept 2017], PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. www.PromarkerD.com
PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its report titled Biomarkers Enabling Diabetes and Obesity Management [ASX: 27 March 2017]. PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending. Further information is available through the PromarkerD web portal.
Proteomics International Laboratories Ltd (PILL) (www.proteomicsinternational.com)
Proteomics International (ASX: PIQ) is a medtech company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities on the QEII Medical Campus in Perth, W. Australia.
Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD. The company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker(TM) technology platform to create a pipeline of novel diagnostic tests.
Dr Richard Lipscombe
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: [email protected]
Head of Business Development
T: +1 617 331 2975
E: [email protected]
Public Relations & Media Contact
Digital Mantra Group
T: +61 2 8218 2144 or +1 415-951-3228
E: [email protected]
About Proteomics International Laboratories Ltd (PILL)
Proteomics International (ASX: PIQ) is a medtech company focused on proteomics - the industrial scale study of the structure and function of proteins. Proteomics technology is now playing a key role in understanding disease, from identifying new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.
Proteomics International is recognised as a global leader in the field of proteomics, receiving the world's first ISO 17025 laboratory accreditation for proteomics services. PILL is located in state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. To learn more, please visit www.proteomicsinternational.com.
Source: Proteomics International Laboratories Ltd (PILL)
Sectors: BioTech, HealthCare
Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
Honda's Cumulative Worldwide Power Products Production Reaches 150 million Units
Sep 19, 2019 20:20 JST
Eisai to Present Latest Data on Lemborexant at World Sleep Congress
Sep 19, 2019 20:06 JST
Toyota to Invest R$1 Billion in its Plant in Brazil to Produce New Vehicle
Sep 19, 2019 14:11 JST
Fujitsu Launches IoT Measuring device for more efficient measurements in the Apparel Industry
Sep 19, 2019 11:41 JST
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019
Sep 18, 2019 21:40 JST
Mitsubishi Motors Hosts World Debuts of Small Electric SUV Concept Car at 46th Tokyo Motor Show 2019
Sep 18, 2019 21:31 JST
KDDI Joins Merpay, LINE Pay, and NTT DOCOMO's Merchant Alliance "Mobile Payment Alliance (MoPA)"
Sep 18, 2019 21:19 JST
DOCOMO to Commence Deployment of World's First 4G/5G Multi-vendor Radio Access Network Conforming to O-RAN Specifications
Sep 18, 2019 15:12 JST
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 18, 2019 14:58 JST
MHI-MME to Take Over Production of MET Turbochargers
Sep 18, 2019 14:46 JST
KAHRAMAA, QEWC and MHPS Sign MOU on Internship Program for Young Qatari Engineers
Sep 18, 2019 14:41 JST
Toyota Installs Stationary Fuel Cell Generator Based on the Mirai FC System at its Honsha Plant in Japan
Sep 18, 2019 13:34 JST
Fujitsu Develops Digitization Technology to Quantify Various Walking Characteristics Resulting from Diseases
Sep 18, 2019 11:30 JST
Toyota Injects $391 Million New Investment in its San Antonio Assembly Plant
Sep 18, 2019 07:54 JST
Hitachi to Integrate Hitachi Vantara and Hitachi Consulting to Accelerate Global Expansion of Hitachi's Social Innovation Business and Digital Growth
Sep 18, 2019 07:42 JST
Eisai Receives IIA Japan Chairman's Award of Institute of Internal Auditors - Japan
Sep 17, 2019 16:42 JST
Toyota Rolls Out Completely Redesigned Corolla, Corolla Touring, and Unveils Improvements to the Corolla Sport in Japan
Sep 17, 2019 13:16 JST
A Power Stage Win and Crucial Points for TOYOTA GAZOO Racing
Sep 17, 2019 09:10 JST
MHI Included in Dow Jones Sustainability Asia Pacific Index for Third Consecutive Year
Sep 17, 2019 01:00 JST
Mitsubishi Motors to Begin Producing the XPANDER in Vietnam in 2020
Sep 16, 2019 09:05 JST